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Abstract: Therapy-related myeloid neoplasm (t
after exposure to chemotherapy or radiotherapy.  t
hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell.  The prognosis 
for patients with t-MN is poor, as current forms of therapy are largely ineffective.  Cytogenetic 
analysis, molecular analysis and gene express
are distinct subtypes of the disease; however, our understanding of the genetic basis of t
incomplete.  Elucidating the genetic pathways and molecular networks that are perturbed in t
MNs,  may  facilitate  the  identification  of  therapeutic  targets  that  can  be  exploited  for  the 
development of urgently-needed targeted therapies. 
Introduction: t-MN is a late complication of cytotoxic 
therapy  (radiation  and/or  chemotherapy)  used  in  the 
treatment  of  both  malignant  and  non
diseases.
1-4 Several  distinct  cytogenetic
subtypes  of  t-MN  are  recognized  that  are
associated with the nature of the preceding treatment.  
Patients who develop t-MN following alkylating agent 
therapy (~75% of cases) typically show a latency of 3
7  years  from  alkylating  agent  expos
years), insidious disease onset with an antecedent MDS 
with  peripheral  cytopenias,  loss,  deletion,  or 
rearrangement of chromosomes 5 and/or 7, and a poor 
prognosis (median survival <8 months).
; Open Journal System 
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related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring 
after exposure to chemotherapy or radiotherapy.  t-MN arises in most cases from a 
hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell.  The prognosis 
MN is poor, as current forms of therapy are largely ineffective.  Cytogenetic 
analysis, molecular analysis and gene expression profiling analysis of t-MN has revealed that there 
are distinct subtypes of the disease; however, our understanding of the genetic basis of t
incomplete.  Elucidating the genetic pathways and molecular networks that are perturbed in t
cilitate  the  identification  of  therapeutic  targets  that  can  be  exploited  for  the 
needed targeted therapies. 
MN is a late complication of cytotoxic 
therapy  (radiation  and/or  chemotherapy)  used  in  the 
treatment  of  both  malignant  and  non-malignant 
Several  distinct  cytogenetic and  clinical 
MN  are  recognized  that  are closely 
associated with the nature of the preceding treatment.  
MN following alkylating agent 
therapy (~75% of cases) typically show a latency of 3-
7  years  from  alkylating  agent  exposure  (median  5 
years), insidious disease onset with an antecedent MDS 
with  peripheral  cytopenias,  loss,  deletion,  or 
rearrangement of chromosomes 5 and/or 7, and a poor 
prognosis (median survival <8 months).
1 Typically, all 
three hematopoietic cell lineages
and  megakaryocytic)  are  involved  in  the  dysplastic 
process  (trilineage  dysplasia),  suggesting  that  the 
disease arises in a multipotent hematopoietic stem or 
progenitor  cell  (HSPC). In  contrast,  patients  who 
develop t-MN following trea
topoisomerase II are  younger,  have a shorter latency 
period (2-3 years), and present with AML. Balanced 
translocations  involving  MLL
21q22,  CBFB at  16q22, or 
(17q12) are common in this subg
these  cytogenetic subsets of  t
committed  progenitor  cell.
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MN) is a distinctive clinical syndrome occurring 
MN arises in most cases from a multipotential 
hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell.  The prognosis 
MN is poor, as current forms of therapy are largely ineffective.  Cytogenetic 
MN has revealed that there 
are distinct subtypes of the disease; however, our understanding of the genetic basis of t-MN is 
incomplete.  Elucidating the genetic pathways and molecular networks that are perturbed in t-
cilitate  the  identification  of  therapeutic  targets  that  can  be  exploited  for  the 
three hematopoietic cell lineages (erythroid, myeloid, 
and  megakaryocytic)  are  involved  in  the  dysplastic 
process  (trilineage  dysplasia),  suggesting  that  the 
disease arises in a multipotent hematopoietic stem or 
In  contrast,  patients  who 
MN following treatment with drugs targeting 
topoisomerase II are  younger,  have a shorter latency 
3 years), and present with AML. Balanced 
MLL at  11q23,  RUNX1 at 
at  16q22, or  PML (15q24) and  RARA
(17q12) are common in this subgroup, suggesting that 
these  cytogenetic subsets of  t-MN  arise  in  a lineage 
committed  progenitor  cell.
3-5 SurvivalMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1.  Cytogenetic abnormalities in 386 patients with t-MN.
Karyotype No. of patients (%)
Normal karyotype 37 (9.6)
349 (90.4)
259 (67)
Clonal abnormalities
Clonal abnormalities of chromosomes 5, 7, or both (+/- other 
abnormalities)
          Abnormal chromosome 5 only 79 (20)
95 (25)
85 (22)
          Abnormal chromosome 7 only
          Abnormal chromosomes 5 and 7
Recurring balanced rearrangements
a 41 (10.6)
          t(11q23) 16 (3)
10 (3)
8 (2)
7 (2)
          t(3;21) or t(8;21) or t(21q22)
          t(15;17)
          inv(16)
Recurring unbalanced abnormalities
a 21 (5)
          +8 10 (3)
3 (1)
8 (2)
          -13/del(13q)
          -Y,+11,del(11q),del(20q),+21
Other clonal abnormalities 29 (7.5)
a: One patient with an abnormality of chromosome 5 and t(3;21), and is listed twice in the table.
times  of  t-MN  patients  are  often  short,  because  this 
disorder is less responsive to current forms of therapy 
than is AML de novo.
1,3,4
t-MN  represents  an  important  model  for  cancer.  
The  incidence  of  t-MN  is  rising,  as  a  result  of  the
increasing  number  of  cancer  survivors  at  risk  of 
developingthis disorder and the changes in therapeutic 
trends. Secondly, t-MN provides a unique opportunity 
to examine the effects of mutagens on carcinogenesis 
in humans, as well as the role of genetic susceptibility 
to cancer.
3 Finally, the mechanisms of leukemogenesis 
that are uncovered in t-MN will likely apply to those 
subtypes  of  AML  de  novo,  which  share  the  same 
cytogenetic abnormalities,  e.g.,  AML  de  novo with 
abnormalities of chromosome 5 or 7.  In this chapter, 
we review the genetic characteristics of t-MN with an 
emphasis on defining the genetic pathways leading to t-
MN with a del(5q).
Cytogenetic  Analyses: Table  1 summarizes  the 
cytogenetic pattern in the recently updated University 
of Chicago series of 386 consecutive patients with t-
MN. Of these, 349 (90.4%) had a clonal chromosomal 
abnormality,  including  259  (67%)  with  a  clonal 
abnormality  leading  to  loss,  deletion,  or 
rearrangements of chromosomes 5 and/or 7 (referred to 
as del(5q)/t(5q) and -7/del(7q) herein),
4 (Le Beau and 
Larson, unpublished data). Overall, 164 patients (42%) 
had  abnormalities  of chromosome  5,  and  180  (47%) 
had abnormalities of chromosome 7.  Of these patients, 
eighty-five  patients  had  abnormalities  of  both 
chromosomes  5  and  7.  A  del(5q)  was  the  most 
common  structural  abnormality.  The  pattern  of 
numerical  and  structural  abnormalities  is  shown  in 
Figure 1, and illustrates that t-MN is associated with a 
complex karyotype, with a predominance of the loss of 
genetic material.  
In  other  studies,  we  evaluated  the  cytogenetic 
pattern of 3,444 patients with primary MDS, AML de 
novo, or t-MN evaluated over the past 35 years by our 
Cancer Cytogenetics Laboratory.  Of these, 553 (16%) 
patients  had  del(5q)/t(5q),  and  597  (17.3%)  had  -
7/del(7q) (Le Beau et al., unpublished data).  Complex 
karyotypes  were  associated  with  abnormalities  of 
chromosome 5, rather than chromosome 7.  Recurring 
abnormalities observed at a high frequency (>20%) in 
patients with del(5q) included +8, and loss of 13q, 16q, 
17p (40% of cases), chromosome 18, and 20q, which 
frequently occured in the same clone (Figure 1, and 
data not shown). 
Identification  of  Haploinsufficient  Myeloid 
Suppressor  Genes  on  5q:  Several  groups  of 
investigators  have  defined  a  commonly  deleted 
segment    (CDS)  on  the  long  arm  of  chromosome  5 
predicted to contain a myeloid tumor suppressor gene.
6-
8 Using cytogenetic and molecular analysis of MDS, 
AML and t-MN with a del(5q), we previously defined 
a  region  of  970  kilobase  within  5q31.2,  flanked  by 
D5S479  and  D5S500,  that  is  deleted  in  all  patientsMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Cytogenetic abnormalities in patients with t-MN (N=386) in the University of Chicago series.  Gain of chromosomal material is 
depicted by green bars to the right of each chromosome, and loss of chromosomal material is depicted by red bars.  Numbers above the bars 
indicate the number of patients with this abnormality.  Arrowheads identify the location of the breakpoints of structural rearrangements.
(Figure 2), and determined the genomic sequence of 
this  region.
6,9 In  subsequent  studies,  we  generated  a 
transcript map of the CDS, and identified and cloned 
19 genes;
9 the CDS also contains one miRNA.  The 
functions of the proteins encoded by these genes are 
diverse, and include the regulation of mitosis and the 
G2  checkpoint,  transcriptional  control,  and 
translational regulation.  
MDS with an isolated del(5q) (the 5q- Syndrome) is 
a  distinct  subtype  of  MDS,  characterized  by  a 
macrocytic  anemia,  female  predominance,  and  a 
favorable outcome, with a low risk of transformation to 
AML.
10 Boultwood and colleagues identified a 1.5 Mb 
CDS  within  5q33.1  between  D5S413  and  GLRA1 .
8
This  region is  distal to the  CDS in  5q31.2 found in 
patients  with  AML  with  a  del(5q). In summary,  the 
existing  data  suggest  that  there  are  two  non-
overlapping CDSs: 5q31.2 in the more aggressive form 
of MDS, AML de novo, and t-MN, and 5q33.1 in the 
5q- Syndrome (Figure 2).
Despite intense efforts, the identification of tumor 
suppressor genes (TSGs) on chromosomes 5 and 7 has 
been  challenging.  Molecular  analysis  of  the  19 
candidate genes within the CDS of 5q31.2 performed 
in our laboratory, and by Graubert et al., did not reveal 
inactivating mutations in the remaining alleles, nor was 
there evidence of transcriptional silencing (Godley and 
Le  Beau,  unpublished  data).
9,11 Similarly,  molecular 
analysis of all 44 genes mapping to the CDS in 5q33.1 
in  the  5q- Syndrome  did  not  reveal  inactivating 
mutations.
8 These observations are compatible with a 
haploinsufficiency model in which loss of one allele of 
the  relevant  gene(s)  on  5q  perturbs  cell  fate .
12 A 
number of genes located on 5q, including RPS14 ,
13
EGR1,
14 NPM1,
15 APC,
16 CTNNA1,
17 HSPA9,
18 and 
DIAPH1,
19 have been implicated in the development of 
myeloid disorders due to a gene dosage effect, and are 
reviewed briefly below. Together, these studies support 
a haploinsufficiency model, in which loss of a single 
allele of more than one gene on 5q contributes to the 
pathogenesis of t-MN with del(5q). 
RPS14: The gene encoding RPS14, which is required 
for  the  processing  of  18S  pre-rRNA,  is  located  at 
5q33.1, and was identified as a candidate disease gene 
in  the 5q- Syndrome.
13 Downregulation of  RPS14 in 
CD34+ bone marrow cells blocks the differentiation of 
erythroid  cells,  and  increases  apoptosis  in 
differentiating  erythroid  cells  in  vitro.  Studies  in  a 
mouse  model  suggest  that  a  TP53-dependent 
mechanism underlies this syndrome.
20 Of interest, the 
ribosomal  processing  defect  caused  by 
haploinsufficiency of RPS14 in the 5q- Syndrome is
highly  analogous  to  the  functional  ribosomal  defectMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 2. Idiogram of the long arm of chromosome 5 showing candidate genes within the CDSs as reported by various investigators.  The 
proximal CDS in 5q31.2 was identified in MDS, AML and t-MN, whereas the distal CDS in 5q33.1 was identified in MDS with an isolated 
del(5q) (the 5q- Syndrome).
seen in Diamond-Blackfan anemia.  Other studies have 
shown  that  haploinsufficiency  of  two  micro-RNAs 
(miRNAs) that are abundant in HSPCs, miR-145 and 
miR-146a, are encoded by sequences near the RPS14
gene, and cooperate with loss of RPS14.
21,22 The Toll-
interleukin-1  receptor  domain-containing  adaptor 
protein  (TIRAP)  and  tumor  necrosis  factor  receptor-
associated factor-6 (TRAF6) are respective targets of 
these miRNAs, implicating inappropriate activation of 
innate immune signals in the pathogenesis of the 5q-
Syndrome.
21 miR-145  also  targets  FLI1,  a  gene  that 
promotes thrombocytopoiesis.
22 Haploinsufficiency of 
miR-145 may account for several features of the 5q-
Syndrome,  including  megakaryocytic  dysplasia; 
however,  neither  RPS14 nor  miR-145 
haploinsufficiency  is  predicted  to  confer  clonal 
dominance.  
NPM1: NPM1 is involved in ribosome biogenesis and 
centrosome duplication, and modulates the activity of 
the  TP53  and  CDKN2A  tumor  suppressors.    Npm1
heterozygous  mice  develop  erythroid  dysplasia  with 
elevated  mean  corpuscular  volume  and  red  cell 
distribution  width,  normal  red  blood  cell  counts  and 
hemoglobin  (Hb)  levels,  and  dysplastic 
megakaryocytes.
15 However, the role of NPM1 in the 
pathogenesis of MDS/AML is unclear, since NPM1 is 
not deleted in most patients with a del(5q), nor have 
NPM1 mutations  been  identified  in  patients  with  a 
del(5q).
23
CTNNA1: Liu  et  al. showed that  the  -catenin  gene 
(CTNNA1) is  down-regulated in  stem and progenitor 
cells from MDS and AML patients with a del(5q) as 
compared  to  patients  lacking  del(5q),  or  normal 
HSPCs.
17 CTNNA1  is  suppressed  due  to  epigenetic 
silencing in HL-60 cells, a myeloid leukemia cell line 
used as a model for del(5q) leukemia. Reinduction of 
CTNNA1 expression led to reduced proliferation, and 
an  increased  frequency  of  apoptosis,  suggesting  that 
down-regulation of -catenin in HSPCs may contribute 
to  transformation  of  myeloid  cells  in  AML  patients 
with  a  del(5q).
17 However,  analysis  of  mice  with  a 
conditional knockout of Ctnna1 in hematopoietic cells 
(Ctnna1+/-), revealed no defects in hematopoiesis, or 
predisposition  to  myeloid  neoplasms  following 
mutagenesis with N-ethyl-nitrosourea (ENU).
24
HSPA9: Heat shock protein A9 (HSPA9, also known 
as  mortalin)  is  a  highly  conserved  HSP70  family 
member  that  serves  as  a  protein  chaperone.  
Stimulation  of  hematopoietic  progenitor  cells  with 
erythropoietin (EPO) results in upregulation of HSPA9, 
which may serve as a mediator of EPO signaling.  The Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
HSPA9 gene is distal to the CDS in 5q31.2; however, 
one allele of this gene is deleted in the vast majority of 
cases. Using lentiviral-mediated knockdown in primary 
human  hematopoietic  cells  and  in  a  murine  bone 
marrow-transplantation model, Chen et al. found that
knockdown  of  HSPA9 in  human  cells  significantly 
delayed  the  maturation  of  erythroid  precursors, 
increased  apoptosis  and  decreased  cell  cycling; 
myeloid  and  megakaryocytic  precursors  were  not 
affected.
18In  the  murine  Hspa9-knockdown  model, 
HSPCs,  megakaryocyte/erythrocyte  progenitors, 
erythroid  precursors,  and  B  lymphocytes  were 
significantly reduced in number, suggesting that Hspa9 
haploinsufficiency  contributes  to  abnormal 
hematopoiesis.  Nonetheless,  additional  cooperating 
gene  mutations  would  be  necessary  for  the 
pathogenesis  of  myeloid  disorders  and  clonal 
dominance.  
DIAPH1:  The  gene  encoding  Diaphanous-related 
formin,  mDia1  (DIAPH1),  maps  to  5q31.3,  between 
the  CDSs  identified  in  5q31.2  and  q33.1.  mDia  has 
critical roles in actin remodeling in cell division and in 
response to adhesive and migratory stimuli. Diaph1+/-
and  Diaph1-/- mice  have  normal  hematopoiesis,  but 
develop age-dependent myeloproliferative defects in a 
small  percentage  of  mice.
19 Eisenmann  et  al.,  have 
proposed  that  mDia1  acts  as  a  node  in  a  tumor-
suppressor  network  that  involves  multiple  5q  gene 
products  (RPS14,  EGR1,  CTNNA1,  and  possibly 
APC). The network has the potential to sense dynamic 
changes  in  actin  assembly,  providing  a  homeostatic 
mechanism  that  serves  to  balance  the  regulation  of 
growth control and differentiation in HSPCs. Although 
intriguing,  this  model  awaits  further  experimental 
validation.
APC: APC  (adenomatous  polyposis  coli)  is  a 
multifunctional tumor suppressor that is involved in the 
initiation  and  progression  of  colorectal  cancer  via 
regulation  of  the  WNT  signaling  cascade. The  APC
gene  is  located  at  chromosome  band  5q22.2,  and  is 
deleted in >95% of patients with a del(5q),
6 raising the 
question  of  whether  haploinsufficiency  of  APC
contributes to the development of myeloid neoplasms 
with  loss  of  5q. Qian  et  al.  employed  the  Cre-loxP
system  to  inactivate  Apc in  hematopoietic  cells  in 
vivo.
25 Conditional  inactivation  of  Apc  in  vivo
dramatically  increased  apoptosis  and  enhanced  cell 
cycle  entry  of  HSPCs,  leading  to  their  rapid 
disappearance and bone marrow failure.  Conditional 
inactivation of a single allele of Apc in mice led to the 
development of severe anemia with macrocytosis and 
monocytosis.
16 Further characterization of the erythroid 
lineage revealed that erythropoiesis was blocked at the 
early  stages  of  differentiation.    The  short-term  and 
long-term  hematopoietic  stem  cell  populations  were 
expanded  in  Apc-heterozygous  mice  as  compared  to 
the  control  littermates;  however,  the  HSPCs  had  a 
reduced capacity to regenerate hematopoiesis in vivo in 
the absence of a single allele of Apc. Apc heterozygous 
myeloid  progenitor  cells  displayed  an  increased 
frequency of apoptosis, and decreased in vitro colony-
forming capacity,  recapitulating  several characteristic 
features of myeloid neoplasms with a del(5q).  These 
results indicated that haploinsufficiency of Apc impairs 
hematopoiesis, and raised the  possibility  that  loss of 
function  of  APC contributes  to  the  development  of 
MDS and AML with a del(5q).
EGR1: The  early  growth  response  1  gene  (EGR1)
encodes a member of the WT-1 family of transcription 
factors and contains 3 Cys2His2 Zn fingers that bind the 
GC-rich  consensus  sequences,  GCG(G/T)GGGCG.
26
In  the  mouse,  Egr1 has  been  shown  to  be  an  early 
response gene, and mediates the  cellular response to 
growth factors, mitogens, and stress stimuli.
26 Egr1+/-
or  Egr1-/- mouse  embryonic  fibroblasts  bypass 
senescence  and  have  immortalized  growth 
characteristics,  suggesting  a  role  for  Egr1  as  a 
“gatekeeper”  of  p53-dependent  growth  regulation. 
EGR1 has also been shown to act as a TSG in several 
human tumors, including breast carcinomas and non-
small  cell  lung  cancer.
27 Recently,  Egr1  has  been 
shown to be a direct transcriptional regulator of many 
known TSGs, e.g., Tp53, Cdkn1a/p21, Tgfb and Pten.
27
We  characterized  the  hematopoietic  potential  of 
WT,  Egr1+/-, and  Egr1-/- mice,  and  found  that 
heterozygous or homozygous loss of Egr1 alone under 
normal  physiological  conditions  does  not  affect  the 
hematopoietic potential of murine marrow.
14 However, 
Wagers and colleagues have shown that Egr1-deficient 
mice  show  spontaneous  mobilization  of  HSPCs  into 
the  periphery,  identifying  Egr1  as  a  transcriptional 
regulator  of  stem  cell  migration.
28 To  investigate 
whether  loss  of  Egr1 cooperates  with  secondary 
mutations to induce leukemia in the mouse, we treated 
WT, Egr1+/-, and Egr1-/- mice with a single dose of 
100mg/kg ENU at 4 weeks or 20 weeks of age.  ENU 
was chosen because it is an alkylating agent, and may 
recapitulate  the  effects  of  alkylating  agent 
chemotherapy  in  patients  who  develop  t-MN. ENU-
treated  Egr1+/- and  Egr1-/- mice  developed  a 
myeloproliferative  disorder  with  ineffective 
erythropoiesis (MPD) at a high incidence.  Our data 
suggests that loss of a single allele of Egr1 cooperates 
with mutations induced by an alkylating agent in the 
development of  malignant  myeloid  diseases  in  mice.  
Nevertheless,  Egr1  haploinsufficiency  alone in  vivo
does  not  result  in  expansion  of  the  HSPCs  orMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 3. Retroviral insertional mutagenesis in Egr1+/- mice.  Egr1 WT (n=61) and Egr1+/- (n=77) neonatal mice were injected with 
MOL4070LTR retrovirus. (A) Survival curve for mice that developed myeloid neoplasms. (B) Flow cytometric analysis of spleen cells from 
a typical Egr1+/- diseased mouse revealed a Gr-1+Mac1+ myeloid neoplasm. (C, D) Wright-Giemsa-stained peripheral blood and bone 
marrow smears from a mouse with a myeloid neoplasm.
abnormalities in adult hematopoiesis.
14
To identify genes that cooperate with loss of Egr1
in  murine  leukemogenesis,  we  are  using  a  forward 
genetic screen by retroviral insertional mutagenesis.
29
We have injected cohorts of wild  type (WT) (n=61) 
and  Egr1+/- (n=77) neonatal  mice  with  the 
MOL4070LTR  retrovirus.  WT  and  Egr1+/- mice 
developed disease at an onset of 7 mos. of age. Egr1+/-
mice develop AML or an MPD-like leukemia with a 
shorter latency and at a higher overall frequency than 
WT littermate controls (median survival: Egr1 WT 456 
days, Egr1 +/-  397 days, p=0.038) (Figure 3).  Of note 
is  that the incidence of myeloid disease is higher in 
Egr1+/- mice  (68%)  than  in  WT  mice  (49%), 
indicating  that  loss  of  one  allele  of  Egr1 shifts  the 
disease  spectrum  from  the  more  common  lymphoid 
neoplasm  to  myeloid  neoplasms.  To  identify 
cooperating cancer genes, we have cloned over 1500 
retroviral  integrations  from  myeloid  neoplasms 
developing  in  11  Egr1 WT  and  19  Egr1+/- mice.  
Ligation-mediated polymerase chain reaction was used 
to  identify  retroviral  integrations  at  30  common 
integration  sites.  The  most  common  integration  site 
was upstream of the Evi1 gene.  Of particular interest, 
16/33  (48%)  of  Egr1+/- mice,  as  compared  to  5/17 
(29%) of Egr1 WT mice had elevated Evi1 expression 
in  spleen cells from diseased mice, which correlated 
with retroviral integrations upstream of Evi1. 
EVI1 is overexpressed in AMLs, and is associated 
with  a  poor  prognosis.  Activation  of  EVI1 in 
hematopoietic cells can occur by juxtaposition of the 
gene  to  enhancer  elements  of  the  ribophorin  gene 
located  at  3q21  as  a  result  of  the 
inv(3)(q21q26.2)/t(3;3)(q21;q26.2)  and, in  the 
t(3;21)(q26.2;q22), as part of the fusion RUNX1/EVI1
mRNA transcribed from the der(3) chromosome. EVI
is also overexpressed in 70% of AMLs with -7/del(7q), 
as well as in AMLs with translocations involving MLL
at  11q23,  and  in  many  cases  with  a  complex 
karyotype.
30,31
EVI1 encodes a transcription factor that contains a 
seven-zinc-finger  domain  at  the  N-terminal  end,  a 
three-finger domain in the central part of the molecule, 
and an acidic domain distal to the second group of zinc 
fingers. EVI1 interacts with a number of transcriptional 
and  epigenetic  regulators  (CREBBP,  CTBP,  HDAC, 
KAT2B  (P/CAF),  SMAD3,  GATA1,  GATA2, 
DNMT3A,  and  DNMT3B),  and  mediates  chromatin 
modifications and DNA hypermethylation.  Depending 
on  it’s  binding  partners,  EVI1  can  act  as  a 
transcriptional activator to promote the proliferation of 
HSPCs,  e.g.,  when  bound  to  GATA2,  or  as  a 
transcriptional  repressor  inhibiting  erythroid 
differentiation,  e.g.,  when  bound  to  GATA1.    In 
addition, EVI1 impairs myelopoiesis by de-regulation 
of multiple transcription factors, including RUNX1 and 
PU.1.
32,33 This data raises the possibility that there are 
unique  EVI1  interactions  in  each  cytogenetic  risk 
group  that  contribute  to  the  development  of  disease.
Engineered over-expression of EVI1 in hematopoietic 
cells  of  transgenic  mice  or  via  bone  marrow 
transplantation does not result in leukemia, indicating 
that  additional  cooperating  genetic  mutations  are 
required  for  the  pathogenesis  of  myeloid  neoplasms.  Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
In the case of del(5q), haploinsufficiency of EGR1 in 
concert  with  high  EVI1  may  act  to  promote 
proliferation and self-renewal of HSPCs as well as to 
disrupt erythroid and myeloid differentiation.  
HNRNPA0: A core set of genes has been identified as 
“master regulators” of myeloid differentiation.  At the 
level of the granulocyte-monocyte progenitor, overall 
fate determination involves a balance of two opposing 
forces:  PU.1  promotes  monocytic  differentiation,
whereas CEBPA promotes granulocytic differentiation.  
Monocytic  differentiation  is  promoted  by  the  PU.1-
induced  transcription  factors  EGR2  and  NAB2, 
whereas  granulocytic  differentiation  is  promoted  by 
GFI1.  EGR1/2 and NAB2 have been found to suppress 
the expression  of  GFI1 and  its  downstream  targets; 
conversely,  GFI1  suppresses  EGR1,  EGR2 and 
NAB2.
34 In  the  context  of  the  del(5q),  EGR1 
haploinsufficiency  would  be  expected  to  deregulate 
myeloid cell differentiation, favoring granulocytic over 
monocytic differentiation.  The HNRNPA0 gene is also 
located within the CDS of 5q31.2, and is expressed at 
reduced levels in CD34+ cells from patients with MDS 
characterized  by  a  del(5q)  (Young  and  Le  Beau, 
unpublished data). The HNRNPA0 protein is a member 
of the hnRNPA/B family of RNA-binding proteins, and 
has  been  shown  to  regulate  transcript  stability  via 
binding  to  the  AU-rich  element  of  mRNAs. Using 
shRNAs  in  mouse  hematopoietic  cells,  we 
demonstrated that knockdown of Hnrnpa0 leads to a 
decrease in the stability of Egr2 transcripts (Young and 
Le  Beau,  unpublished  data). Thus,  loss  of  a  single 
allele of EGR1 and HNRNPA0 as a result of a del(5q) 
may lead to a synergistic disruption of EGR1/2 activity 
during leukemogenesis.
Alterations  in  Gene  Function: A  growing  body  of 
evidence suggests that mutations of multiple genes are 
involved in the pathogenesis and progression of t-MN.  
The involved genes fall into two main classes, namely, 
genes encoding hematopoietic transcription factors or 
proteins  that  regulate  cytokine signaling  pathways 
(Table 2).  The RAS signaling cascade is downstream 
of a number of activated cytokine receptors, including 
the  FLT3,  IL3,  and  GM-CSF  receptors;  thus,  this 
signaling  pathway  plays  a  pivotal  role  in 
hematopoiesis.  Constitutively  activating  point 
mutations of NRAS, typically involving codons 12, 13, 
or  61,  have  been  detected  at  high  frequency  in 
hematological  malignancies  (10-15%  in  t-MN).
35
Mutations of the  FMS-like  tyrosine kinase 3 (FLT3) 
gene,  including  both  point  mutations  within  the 
tyrosine  kinase  domain  and  internal  tandem 
duplications  (ITDs),  are  among  the  most  common 
genetic  changes  seen  in  AML  de  novo (15-35%  of 
cases),  but  are  less  common  in  t-MN  (0-12%).
35,36
Mutations  of  NPM1 also  occur  frequently  in  AML 
(35% of adult cases), but are less frequent in patients 
with recurring cytogenetic abnormalities, and in t-MN 
(4-10%).  Of note, the NPM1 gene located at 5q35 is 
not mutated in MDS with a del(5q).
15
Table 2. Frequency of gene mutations in AML de novo and t-MN.
Mutated Gene AML de novo t-MN
FLT3 (ITD) 35% 0-10%
FLT3 (TKD) 9% <1%
NRAS 10-15% 10%
KIT
D816 ~5% NA
MLL (ITD) 3% 2-3%
RUNX1 10-15% 15-30%
TP53 10% 25-30%
PTPN11 ~2% 3%
NPM1 35-50% 4-10%*
CEBPA 6-15% Rare
JAK2
V617F 2-5% 2-5%
IDH1/2 15% <10%
TET2 5-15% 15-30%
ASXL 5% 15-40%
EZH2 5% 6-25%
NPM1 mutations are associated with a normal karyotype in t-MN. 
The  Runt-related  transcription  factor  1  gene 
(RUNX1),  also  known  as  AML1,  encodes  the  DNA-
binding  subunit  of  the  heterodimeric core-binding 
factor (CBF) complex, which is essential for definitive 
hematopoiesis.   Point  mutations in  the  RUNX1 Runt 
(DNA-binding)  domain  have  been  reported  in  AML 
and MDS (10-15%), particularly in MDS secondary to 
atomic  bomb  radiation  exposure  or  treatment.  
Similarly, the incidence is higher in t-MN (15-30%).
37
Moreover,  RUNX1 mutations  are  associated  with 
activating mutations of the RAS pathway, -7/del(7q), 
and a shorter overall survival.  
The  TP53 tumor  suppressor  gene  encodes  an 
essential checkpoint protein that monitors the integrity 
of  the  genome,  and  arrests  cell  cycle  progression  in 
response  to  DNA  damage.  Mutations  of  TP53 are 
observed in primary MDS and AML de novo (5-10%) Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
and,  more  commonly,  in  t-MN  (25-30%).
35,38 The 
spectrum of mutations includes missense mutations in 
exons  4-8,  as  well  as  loss  of  the  wild  type  allele, 
typically  as  a  result  of  a  cytogenetic  abnormality  of 
17p.  In t-MN,  TP53 mutations are  associated with -
5/del(5q) and a complex karyotype.  
The role of epigenetic changes in the pathogenesis 
and  treatment  of  MDS  and  AML  is  becoming 
increasingly  important.  Transcriptional  silencing  via 
DNA methylation of the CDKN2B (p15
INK4B) gene is 
observed in a high percentage of patients with t-MN, 
and  is  associated  with  -7/del(7q),  and  a  poor 
prognosis.
39,40 Other  genes  that  may  be  affected  by 
DNA methylation include the CTNNA1 gene on 5q.
Transcriptome  Sequencing  of  t-MN:  To  identify 
expressed  genetic  variants  that  distinguish  the  two 
subtypes  of  t-MN,  we  have  used  next  generation 
sequencing  of  the  mRNA  transcriptome  of  primary 
patient leukemia samples. This technology has become 
significantly  faster  and  cheaper,
41 and  has  several 
advantages  over  other  systems-level  genomic 
approaches.    Although  whole  genome  sequencing  of 
two  de  novo AML  leukemias  identified  several 
mutations,
42,43 mRNA  sequencing  enables  analysis 
across a larger and more diverse set of samples at a 
fraction of  the  cost  and  time.  Transcriptome 
sequencing better distinguishes expression levels and 
mRNA  isoforms  as  compared  to  microarray 
analysis,
44,45 and enables identification of cryptic gene 
fusions  that  cannot  be  detected  by  cytogenetic 
analysis.
46 In addition to expression data, this method 
enables genotyping of the expressed coding region of 
the  genome  to  identify  inherited  polymorphisms  and 
somatic mutations.
47
We  hypothesized  that  the  two  t-MN  subgroups, 
alkylating agent-related and topoisomerase II inhibitor-
related,  have  unique,  genome-wide  patterns  of 
transcriptionally expressed genetic variation that drive 
leukemogenesis.  To  test  this,  we  employed  Illumina 
paired-end technology to sequence the mRNA from the 
leukemia cells of 23 patients with t-MN (McNerney et 
al.,  unpublished  data).  These  are  comprised  of  13 
samples  with  del(5q)  or  -7/del(7q), or  with  complex 
karyotypes,  and  12  cases  with  other  karyotypes, 
including  a  normal  karyotype  or  a  balanced 
translocation.  In  addition,  leukemia  cells  from13
patients  with  AML  de  novo with  a  spectrum  of 
cytogenetic  abnormalities  comparable  to  the  t-MN 
samples were similarly analyzed. 
Interestingly,  there  are  significant  differences 
between t-MN and AML de novo samples at the level 
of  gene  expression.  t-MN  samples  exhibit  different 
gene expression patterns as well as variable usage of 
transcript  isoforms.  This  implies  that  there  are 
underlying  genetic  differences  between  t-MN  and 
AML de  novo,  consistent  with  the  fundamental 
biological differences between these two diseases. In 
addition,  there  is  significant  differential  gene 
expression  between  leukemias  with  abnormalities  of 
chromosomes 5 and/or 7, as compared to those with 
other  cytogenetic  patterns.  By  comparing  RNA-
sequencing  data  to  genome  wide  copy  number 
variation using single nucleotide polymorphism arrays, 
we are identifying those genes (genome-wide as well 
as those mapping to chromosomes 5 and 7) that exhibit 
expression level differences secondary to DNA-dosage 
effects. 
Using  the  RNA-sequencing  data  to  genotype  the 
samples, over 13,000 single nucleotide variants (SNVs) 
have been identified per sample,  which is  similar in 
number  to  other  cancer  samples.    Phenotypically 
relevant SNVs are prioritized by population-level allele 
frequency estimates, evolutionary constraint estimates, 
and the predicted coding region change. This analysis 
yields  approximately  200  rare,  predicted  deleterious 
SNVs  per  sample.  Some  of  these  variants  include 
mutations that were previously reported in AML, such 
as mutations involving the FLT3, TP53, RUNX1, and 
TET2 genes.  However,  mutations  have  not  been 
reported  previously  in  t-MN  in  most  of  the  genes 
containing these variants, and many frequently occur in 
the  same  gene  or  pathway  in  multiple  samples.  A 
subset  of  the  genes  carry  rare,  deleterious  variants, 
which  occur  preferentially  in  leukemias  with 
abnormalities of chromosome 5 and/or 7.  Intriguingly, 
the  vast  majority  of  rare,  deleterious  variants  are 
inherited, which may guide us towards defining genetic 
predispositions to malignancy, in general, and to t-MN 
in particular. It is expected that genome-wide analyses 
across  a  large  number  of  samples  will  result  in  the 
identification  of  the  spectrum  and  frequency  of 
expressed genetic variants in  t-MN subtypes and the 
clinical impact of deleterious variants. 
Models  for  the  Pathogenesis  of  t-MN:  Extensive 
experimental  evidence  indicates  that  more  than  one 
mutation  is  required  for  the  pathogenesis  of 
hematological  malignant  diseases.    Moreover,  these 
mutations  cooperate  to  confer a  proliferative  and/or 
antiapoptotic  activity,  as  well  as  impair  normal 
differentiation  pathways.  Haploinsufficiency  for  a 
gene(s)  on  7q  and  5q  is  likely  to  be  an  initiating 
mutation.  Pedersen-Bjergaard  and  colleagues  have 
proposed  8  different  pathways  that  are  involved  in 
progression to t-MN.
48 Pathway I consists of patients 
who  have  abnormalities  of  chromosome  7,  without 
chromosome  5  abnormalities.  These  patients  often 
present  with  mutations  of  the  RAS  pathway  (KRAS, 
NRAS,  NF1,  PTPN11),  and  methylation  silencing  ofMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 4.  Cooperating genetic mutations leading to t-MN with a del(5q).  
p15 (CDKN2B), and they have a poor prognosis. Loss 
of TAL1, GATA1, and EKLF expression in t-MN with a 
-7/del(7q)  may  result in  impaired  differentiation, 
whereas overexpression of FLT3, PIK3C2B, and BCL2
result in a proliferative/survival advantage.
49 Pathway 
II comprises  patients with a  del(5q)  with  or without 
abnormalities of chromosome 7, and a poor prognosis 
(Figure  4).  Haploinsufficiency  of  multiple, 
cooperating genes on 5q is likely to be the initiating 
event.  Genomic  instability  and  complex  karyotypes 
with gain of chromosome 8, and loss of 12p, 13q, 16q, 
17p (TP53 locus), chromosome 18, and 20q, as well as 
mutations of TP53 are often observed in this subgroup.
In t-MN  patients  with  del(5q),  loss  of  expression of 
IRF8 may  lead to  impaired  differentiation  and/or  a 
survival advantage,  whereas  increased  expression  of 
cell  cycle  regulatory proteins  (CCNA2,  CCNE2, 
CDC2) would result ina proliferative advantage.
49
Pathway III consists of patients with translocations 
of 11q23. Alterations of pathway IV convey the best 
prognosis  for  patients  with  t-MN,  and  include  the 
t(8;21) or inv(16). Pathway V comprises patients who 
present  with  therapy-related  acute  promyelocytic 
leukemia with the t(15;17) resulting in the PML-RARA 
fusion  and  a  good  prognosis.  Pathway  VI  involves 
balanced translocations of NUP98 at 11p15.  Pathway 
VII includes t-MN with a normal karyotype. Recently, 
internal tandem duplications  of  FLT3 and  MLL,  and
NPM1 mutations have been described in a few of these 
patients.  Pathway  VIII  includes  patients  with  other 
chromosomal abnormalities. New technologies, such as 
high-throughput genomics technologies, will facilitate 
further delineation of the genetic pathways leading to t-
MN.  
Concluding Remarks: t-MN remains one of the most 
adverse  complications  of  successful  therapy  for  a 
variety  of  malignant  and  non-malignant  conditions.  
The  factors  that  place  individual  patients  at  risk  are 
beginning  to  be  elucidated,  and  are  critical  for  risk-
assessment, to allow individualized therapy directed at 
minimizing  the  development  of  this  disease.  
Moreover,  characterizing  the  genetic  pathways  that 
give rise to t-MN will lead to a greater understanding 
of genetic susceptibility to this disease, as well as the 
molecular features of the disease and, ultimately, may 
lead to more targeted therapies for its treatment.  
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